Evidence map›Paper›PMID 41515303›Full record

ArticleMolecules (Basel, Switzerland)2025

Preparation of ESAT6-Fc Fusion Protein and Its Therapeutic Efficacy and Immune Mechanisms in Allergic Asthma Mice via Intranasal Immunization.

Jing Wang, Maiyan Hai, Yuxin Yang, Tiansong Wang, Wei Zhang, Rui Ma, Miao Sun, Yanyan Qin, Yuan Yang, Zihan Dong and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jing WangDepartment of Pathogenic Biology and Immunology, College of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.
Maiyan HaiDepartment of Pathogenic Biology and Immunology, College of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.ORCID 0009-0001-9636-0435
Yuxin YangDepartment of Pathogenic Biology and Immunology, College of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.
Tiansong WangDepartment of Pathogenic Biology and Immunology, College of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.
Wei ZhangDepartment of Pathogenic Biology and Immunology, College of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.
Rui MaDepartment of Pathogenic Biology and Immunology, College of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.
Miao SunDepartment of Pathogenic Biology and Immunology, College of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.
Yanyan QinDepartment of Pathogenic Biology and Immunology, College of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.
Yuan YangDepartment of Pathogenic Biology and Immunology, College of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.
Zihan DongDepartment of Pathogenic Biology and Immunology, College of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.
Maosheng YangDepartment of Natural Resource Management and Environmental Geography, College of Geographic Sciences and Planning, Ningxia University, Yinchuan 750021, China.
Qiaofeng WanDepartment of Pathogenic Biology and Immunology, College of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.ORCID 0000-0003-1228-0495

Funding

the Ningxia Natural Science Foundation No.2024AAC03283the Ningxia Natural Science Foundation No.2025AAC030658
6 · The paper itself

Abstract

The respiratory mucosal system plays a critical role in the pathogenesis of allergic asthma (AA). Currently, therapeutic Fc fusion proteins are as a promising strategy for mucosal vaccine delivery systems. In this work, a plasmid encoding the Mycobacterium tuberculosis ESAT6-Fc fusion protein was successfully constructed, and high-purity ESAT6-Fc fusion protein was subsequently obtained. Administered via intranasal immunization in OVA-induced allergic asthma model mice, ESAT6-Fc fusion protein significantly alleviated airway inflammation and mucus production, and reduced the proportions of Th2 cells, Th17 cells, and eosinophils, while increasing the proportions of Th1 cells with no histopathological changes to major organs. To elucidate the underlying immune regulatory mechanisms of ESAT6, integrated transcriptomic and proteomic analyses were performed, revealing Th1/Th2 cell differentiation and Th17 cell differentiation as the two most significantly enriched pathways at both the gene and protein levels. CD3e (

Indexed as

Antigens, BacterialAsthmaBacterial ProteinsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsAdministration, IntranasalAnimalsDisease Models, AnimalFemaleImmunizationMiceTh17 CellsTh1 CellsTh2 CellsAntigens, BacterialBacterial ProteinsESAT-6 protein, Mycobacterium tuberculosisImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsAllergic Asthma (AA)ESAT6-Fcintegrated transcriptomic and proteomic analysisintranasal immunizationMycobacterium tuberculosis (Mt.b)

Identifiers

PMID41515303
PMCPMC12787016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.